Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05418972
Title A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II)
Acronym Neo ReNi II
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Melanoma Institute Australia
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS


No variant requirements are available.